Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Feature|Videos|September 24, 2025
Fresenius Kabi Contract Manufacturing: Focused on Your Success
Author(s)Saleem Farooqui, Fresenius Kabi
Saleem Farooqui of Fresenius Kabi explains how the company is addressing today’s pharmaceutical manufacturing needs. Watch this video to learn how these capabilities can help bring products to market successfully.
Sponsored by Fresenius Kabi
In this video, Saleem Farooqui of Fresenius Kabi explains how the company’s contract manufacturing services help bring pharmaceutical products from development through commercialization. He describes Fresenius Kabi’s global network of more than 17 manufacturing and R&D sites—including three US facilities in Illinois, North Carolina, and New York—and emphasizes the breadth of capabilities they offer. Farooqui highlights their sterile fill-finish expertise for biologics, small molecules, emulsions, lipids, and simple solutions, produced in formats such as vials, pre-filled syringes, IV bags, ampoules, and blow-fill seal. He also underscores the company’s strong culture of quality and compliance, along with a dedicated team that provides regulatory guidance and market support to help products succeed globally.
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.